CRUCELL, DSM TO LICENSE PER.C6 CELL LINE TECHNOLOGY TO DENMARK'S SYMPHOGEN

Crucell NV and its manufacturing partner DSM NV said they signed a deal to license Crucell's PER.C6 cell line technology to Danish biotechnology company Symphogen AS. The license agreement allows Symphogen to use PER.C6 for the production of its proprietary recombinant polyclonal antibodies, known as symphobodies. Under the terms of the agreement, Symphogen will pay a signing fee and annual maintenance fees. Further financial details were not disclosed.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/07/15/afx2140253.html)